Sermorelin + Ipamorelin Stack: When to Pick One Over the Combination

Is there any evidence for the combination?

We found no published human study that gave sermorelin and ipamorelin together.

The closest combination data use a different GHRH analogue: a 2026 review notes that CJC-1295 plus ipamorelin improved maximum tetanic tension in mice with glucocorticoid-induced muscle loss, and that the finding is confined to animal studies [11]. Reviews of the field describe promising preclinical work with these peptides and scarce human data [12][13].

The case for stacking rests on receptor differences. Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone that acts at the pituitary GHRH receptor [5]. Ipamorelin is a five-amino-acid peptide that releases growth hormone through the ghrelin/GH-secretagogue receptor rather than the GHRH receptor, a point established in the 1998 discovery work using GHRH and GHRP antagonists [6]. They act at different receptors, but no human study has tested the combination, so the available evidence does not show that combining them improves outcomes.

That gap matters more for ipamorelin than for sermorelin. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin; the human studies used intravenous dosing [1][3][14].

Sermorelin alone: the human record

Sermorelin acetate was approved twice as Geref: a 0.05 mg ampule for testing the pituitary's ability to secrete growth hormone, approved December 28, 1990, and 0.5 mg and 1 mg vials for treating idiopathic growth hormone deficiency in children with growth failure, approved September 26, 1997 [7]. The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, which FDA did effective June 18, 2009 [7]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [7]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [7].

No sermorelin product is FDA-approved today. Sermorelin products sold in the United States are compounded, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [8].

The main human outcome trial was open-label and multicenter, ran one year, and enrolled 110 previously untreated prepubertal children with growth hormone deficiency, 86 of whom were evaluable. They received 30 micrograms/kg subcutaneously at bedtime. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months. No adverse changes in general biochemistry or hormone tests were noted, fasting glucose did not change, and IGF-I was not excessively raised [2].

The smaller human study measured hormones, not outcomes. Ten healthy older men received 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily for 14 days at each dose, in random order. Their hormone levels were compared with those of nine younger men. At the 1 mg dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the younger men [15].

Ipamorelin alone: animal work, one intravenous trial, one failed phase 2

The 1998 discovery paper covered rat pituitary cells, anesthetized rats and conscious swine; ipamorelin released growth hormone with potency and efficacy similar to GHRP-6, and in swine none of the secretagogues tested changed FSH, LH, prolactin or TSH [6]. Most claims about ipamorelin's selectivity come from this animal work.

The human pharmacokinetic study gave healthy men 15-minute intravenous infusions of 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg. Kinetics were dose-proportional, terminal half-life was about 2 hours, clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg. Growth hormone rose in a single peak about 0.67 hours after the infusion and fell to negligible levels at all doses [14].

The one published phase 2 trial was in postoperative ileus, not growth. It was multicenter, randomized, double-blind and placebo-controlled, enrolled 117 adults having bowel resection, and analyzed 114. Patients received 0.03 mg/kg intravenously twice daily or placebo from postoperative day 1 to 7. Median time to first tolerated solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, which was not significant (p=0.15). Secondary gastrointestinal-recovery endpoints did not differ, and only a subgroup of open-surgery patients showed shorter bowel recovery. Any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group versus 94.8% of the placebo group [3]. Development was reportedly discontinued after disappointing phase 2 results [1].

FDA's review of that trial lists low potassium in 12.5% versus 3.4%, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications; FDA said it is unclear whether the deaths were related to ipamorelin but that they raise safety concerns [1]. FDA also expects that stimulating the growth hormone and IGF-1 axis may carry the risks listed on approved growth hormone labels — neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism and pancreatitis — and possibly QT prolongation, as seen with the approved growth hormone stimulator macimorelin. FDA found no data showing ipamorelin would not [1].

Regulatory status

Sermorelin does not appear on FDA's page of bulk substances that may present significant safety risks, content dated 04/22/2026 [4]. It is in category 1 on FDA's nomination list for outsourcing facilities, marked as a component of an FDA-approved drug, on a list updated March 21, 2025 [16], and it appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [17]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [18].

Ipamorelin acetate is in category 2 for outsourcing facilities, added September 29, 2023 and still listed [4][16]. FDA's stated concerns are possible immunogenicity from aggregation and impurities for certain routes, unnatural amino acids that complicate characterization, and a published study reporting serious adverse events including death when ipamorelin was given intravenously for gastric motility; FDA says it has not identified safety-related information for other injectable routes [4]. For state-licensed pharmacies and physicians it appears in the 'nominated but withdrawn' table and in none of the three categories, and FDA's category 1 policy does not apply to it [4][17]. On October 29, 2024 FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base and the same on ipamorelin acetate, citing a lack of information supporting safety and efficacy for growth hormone deficiency and postoperative ileus [19]. It is not in the HHS draft policy either [18].

Both peptides are named in WADA's S2.2.4, covering growth hormone releasing factors and growth hormone secretagogues. They are prohibited at all times, in and out of competition, on the 2026 List and the 2027 List [9][10].

Doses used in studies, not recommendations

Neither peptide has a currently FDA-approved dose: Geref's approvals were withdrawn, and ipamorelin has never been FDA-approved [7][1]. The pediatric Geref program used 30 micrograms/kg subcutaneously once daily at bedtime, and the older-men study used 0.5 mg or 1 mg subcutaneously twice daily for 14 days [2][15]. Human ipamorelin was given intravenously only: 0.03 mg/kg twice daily in the ileus trial and single 15-minute infusions of 4.21 to 140.45 nmol/kg in the volunteer study [3][14].